PRKCB and benign prostatic hyperplasia: ADAMTS12, CCDC181, NAALAD2, and PRKCB demonstrated significantly lower expression levels in cancerous prostate tissue than NPT and BPH samples (all p < 0.0500; Figure 3A–D).